Is Viatris (VTRS) overvalued or fairly valued?

MarketChacha shows Viatris's valuation in context — a forward P/E of about 6.3, a price-to-book of about 1.3 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Viatris's revenue?

Viatris reported revenue of $14.3B for FY2025, with net profit of $-3.5B, per official filings.

What is the share price of Viatris (VTRS)?

Viatris last traded at $16.88 (-0.4% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Viatris

VTRS · NYSE · Healthcare · United States

Snapshot

TickerVTRS

ExchangeNYSE

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

CountryUnited States

Employees30,000

HeadquartersCanonsburg, United States

Websitewww.viatris.com

Filings tracked21

About Viatris

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Who owns it

Insiders0.3%
Institutions93.6%
Public & other6.1%

1,380 institutional holders

Ownership breakdown from public market data.

Top holders

FMR, LLC8.42%
Blackrock Inc.7.49%
Vanguard Capital Management LLC6.62%
Davis Selected Advisers6.55%
Price (T.Rowe) Associates Inc5.94%
Vanguard Portfolio Management LLC4.73%
State Street Corporation4.62%
Rubric Capital Management LP2.97%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Margin has compressed by about 25.0 points over the period — profitability is trending down.

Net margin trend0.4% → -24.7%

Margin has compressed by about 25.0 points over the period — profitability is trending down.

Return on equity-23.9%

Latest ROE of -23.9% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $3.7B · EPS 0.58

Est. earnings growth +2.3%

Next fiscal year

Rev $15.0B · EPS 2.67

Est. earnings growth +6.7%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$14.3B

Net margin

-24.7%

ROE

-23.9%

Revenue CAGR (2y)

-3.8%

EPS (FY2025)

-3.00

Net profit (FY2025)

$-3.5B

Ask MarketChacha about VTRS

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$14.3B	$-3.5B	-3.00	-24.7%	-23.9%
FY2024	$14.7B	$-634.2M	-0.53	-4.3%	-3.4%
FY2023	$15.4B	$54.7M	0.05	0.4%	0.3%

Quarterly

Period	Revenue	EPS
2026Q2	$3.7B	-0.10
2026Q1	$3.5B	0.15
2025Q3	$3.7B	-0.11
2025Q2	$3.6B	0.00
2025Q1	$3.2B	-2.55
2024Q3	$3.7B	0.08
2024Q2	$3.8B	-0.27
2024Q1	$3.7B	0.09
2023Q3	$3.9B	0.27
2023Q2	$3.9B	0.22
2023Q1	$3.7B	0.19

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Results of operations, Other events, Exhibits
SEC8/6/2026material
10-Q filing
SEC8/6/2026
8-K — Material agreement, Material financial obligation, Exhibits
SEC7/1/2026material
8-K — Material agreement, Material financial obligation, Exhibits
SEC6/18/2026material
8-K — Other events, Exhibits
SEC6/15/2026material
8-K — Shareholder vote results
SEC5/15/2026material
8-K — Results of operations, Other events, Exhibits
SEC5/7/2026material
10-Q filing
SEC5/7/2026
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC5/4/2026material
8-K — Results of operations, Costs from exit/disposal, Other events, Exhibits
SEC2/26/2026material
10-K filing
SEC2/26/2026
8-K — Executive/director change
SEC2/3/2026material

2025

8-K — Reg FD disclosure, Exhibits
SEC12/8/2025material
8-K/A — Executive/director change
SEC12/5/2025
8-K — Shareholder vote results
SEC12/5/2025material
8-K — Results of operations, Other events, Exhibits
SEC11/6/2025material
10-Q filing
SEC11/6/2025
8-K — Bylaw/charter change, Other events, Exhibits
SEC10/24/2025material
8-K — Results of operations, Other events, Exhibits
SEC8/7/2025material
10-Q filing
SEC8/7/2025
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC8/5/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.